Studies focused on the FrostBite device platform and cancer response to cryoablation highlight the potential use of this next generation technology for the treatment of pancreatic and esophageal cancer.

August 3, 2016 – Owego, NY – The need for the development of new devices and strategies to treat cancer was front and center at this year’s annual meeting of the Society for Cryobiology held in Ottawa, Canada in the session “Cool Developments in Cryomedicine”. This 2 part, 4-hour session featured 9 presentations focused on new developments in the use of cryo for disease treatment. As part of the session, CPSI scientists presented three studies focusing on molecular studies and device development in the areas of prostate (John M. Baust, Ph.D., CPSI President), pancreatic (Anthony Robilotto, MS., CPSI Engineer) and esophageal cancer (Kristi Snyder, Ph.D., Principal Scientist). Central to these studies was the incorporation of several of CPSI’s new device technologies including the PSN cryoablation device, FrostBite cryoablation catheter and EsoAblate cryoprobe. The FrostBite and EsoAblate cryoprobes are under development for the minimally invasive endoscopic based treatment of pancreatic and esophageal cancer, among other gastrointestinal cancers. The studies included discussion of cancer cell response to freezing, device design and characterization analysis as well as data from a series of studies conducted using tissue engineered pancreas and esophageal cancer models. The presentations also included results from preliminary in vivo studies conducted in conjunction with collaborators at Johns Hopkins Medical which demonstrated the successful translation of CPSI’s engineering and life science development into functional systems capable of delivering of an ultra-cold, highly lethal insult (ablative dose) within a matter of minutes.

Click here to read the full press release: Presentations Feature CPSI’s FrostBite GI Cancer Cryoablation Platform

Contact us to learn more about CPSI’s Cryoablation Medical Device Research & Development Programs

View other CPSI Biotech news and recent patent announcements